Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. (e)-5-(2-bromovinyl)-2'-deoxyuridine
2. (z)-5-(2-bromovinyl)-2'-deoxyuridine
3. 5-(2-bromoethenyl)-2'-deoxyuridine
4. 5-(2-bromovinyl)-2'-deoxyuridine
5. 5-bvdu
6. Brivudin
7. E-5-(2-bromovinyl)-durd
8. Z-5-(2-bromovinyl)-durd
9. Zostex
1. 69304-47-8
2. Bvdu
3. (e)-5-(2-bromovinyl)-2'-deoxyuridine
4. Brivudin
5. Helpin
6. Zostex
7. Bromovinyldeoxyuridine
8. Brivudine [inn]
9. 5-bromovinyldeoxyuridine
10. (e)-5-(2-bromovinyl)-deoxyuridine
11. Rp101
12. Rp-101
13. Uridine, 5-[(1e)-2-bromoethenyl]-2'-deoxy-
14. Uridine, 5-(2-bromovinyl)-2'-deoxy-, (e)-
15. Brivudine (inn)
16. Nsc-633770
17. Ncgc00093656-01
18. 2m3055079h
19. 5-((e)-2-bromovinyl)-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
20. Brivudinum
21. Brivudina
22. Brivudinum [inn-latin]
23. Brivudina [inn-spanish]
24. Mfcd00058585
25. 5-[(e)-2-bromoethenyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
26. Bvd
27. Ccris 2831
28. 5-(2-bromovinyl)-2'-deoxyuridine
29. Nsc 633770
30. Trans-5-(2-bromovinyl)-2'-deoxyuridine
31. Bridic
32. Brivox
33. Zerpex
34. Brvdurd
35. Nsc633770
36. Unii-2m3055079h
37. Uridine, 5-(2-bromoethenyl)-2'-deoxy-, (e)-
38. Bv-durd
39. Zostex (tn)
40. (e)-5-(2-bromovinyl)-2-deoxyuridine
41. Brivudine [mi]
42. Brivudine [mart.]
43. Brivudine [who-dd]
44. Dsstox_cid_25755
45. Dsstox_rid_81098
46. Dsstox_gsid_45755
47. Lopac0_000175
48. Schembl99350
49. Chembl31634
50. Schembl141408
51. (e)-5-(2-bromovinyl)-durd
52. Dtxsid0045755
53. Zinc3653378
54. Tox21_111213
55. Bdbm50366681
56. S5009
57. Ua-618
58. Zb0745
59. E-5-(2-bromovinyl)-2'-deoxyuridine
60. Akos015833980
61. Ccg-204270
62. Cs-6292
63. Db03312
64. Lp00175
65. Sdccgsbi-0050163.p002
66. Ncgc00093656-02
67. 5-[(e)-2-bromoethenyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
68. 5-[(e)-2-bromovinyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
69. As-35234
70. Hy-13578
71. 5-[(e)-2-bromoethenyl]-2'-deoxyuridine
72. Cas-69304-47-8
73. A-176
74. B3404
75. Eu-0100175
76. B 9647
77. D07249
78. 5-((e)-2-bromovinyl)-2'-deoxyuridine
79. Q904107
80. Sr-01000075726
81. J-700153
82. Sr-01000075726-1
83. Bromovinyldeoxyuridine; 5-[(e)-2-bromoethenyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
Molecular Weight | 333.13 g/mol |
---|---|
Molecular Formula | C11H13BrN2O5 |
XLogP3 | -0.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 3 |
Exact Mass | 332.00078 g/mol |
Monoisotopic Mass | 332.00078 g/mol |
Topological Polar Surface Area | 99.1 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 450 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB15 - Brivudine
Global Sales Information
Market Place
ABOUT THIS PAGE
A Brivudine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Brivudine, including repackagers and relabelers. The FDA regulates Brivudine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Brivudine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Brivudine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Brivudine supplier is an individual or a company that provides Brivudine active pharmaceutical ingredient (API) or Brivudine finished formulations upon request. The Brivudine suppliers may include Brivudine API manufacturers, exporters, distributors and traders.
click here to find a list of Brivudine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Brivudine written confirmation (Brivudine WC) is an official document issued by a regulatory agency to a Brivudine manufacturer, verifying that the manufacturing facility of a Brivudine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Brivudine APIs or Brivudine finished pharmaceutical products to another nation, regulatory agencies frequently require a Brivudine WC (written confirmation) as part of the regulatory process.
click here to find a list of Brivudine suppliers with Written Confirmation (WC) on PharmaCompass.
Brivudine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Brivudine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Brivudine GMP manufacturer or Brivudine GMP API supplier for your needs.
A Brivudine CoA (Certificate of Analysis) is a formal document that attests to Brivudine's compliance with Brivudine specifications and serves as a tool for batch-level quality control.
Brivudine CoA mostly includes findings from lab analyses of a specific batch. For each Brivudine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Brivudine may be tested according to a variety of international standards, such as European Pharmacopoeia (Brivudine EP), Brivudine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Brivudine USP).
LOOKING FOR A SUPPLIER?